Education
About Us
Working with TipRanks
Follow Us
Moleculin Biotech (MBRX)
NASDAQ:MBRX
MBRX Stock Chart & Stats
$4.28
-$0.01(-0.56%)
At close: 4:00 PM EST
$4.28
-$0.01(-0.56%)
Day’s Range― - ―
52-Week Range$3.13 - $91.23
Previous CloseN/A
Volume63.82K
Average Volume (3M)2.74M
Market Cap
$13.21M
Enterprise Value-$1.13M
Total Cash (Recent Filing)$6.70M
Total Debt (Recent Filing)$390.00K
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Mar 20, 2026EPS Estimate
-6.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.02
Shares Outstanding3,079,229
10 Day Avg. Volume1,958,319
30 Day Avg. Volume2,738,732
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-0.25
Enterprise Value/Market Cap-0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit13.90
Enterprise Value/Ebitda0.03
Forecast
1Y Price Target
$24.33Price Target Upside468.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ExecutionSteady enrollment progress and planned interim unblinding in the Phase 3 MIRACLE study support the likelihood of a timely efficacy readout and demonstrate operational momentum.
Regulatory PathwayA robust Part A efficacy readout could enable rolling regulatory submissions, creating a clearer path toward accelerated approval and commercialization.
Safety ProfileIndependent assessments found no evidence of heart damage from annamycin across multiple trials, supporting a differentiated anthracycline with reduced cardiotoxicity risk.
Bears Say
Binary Outcome RiskThe investment thesis is heavily dependent on demonstrating clinical efficacy, making the stock highly sensitive to the outcome of pivotal trials.
Financing And Dilution RiskFailure to meet key efficacy milestones could weaken the pipeline rationale and force dilutive financing or strategic partnerships to sustain development.
Share Price VolatilityConcentration of value in pivotal trial results increases the chance of sharp share price swings if interim data disappoint or market expectations shift.
Moleculin Biotech News
MBRX FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $3.13 and its highest was $91.22 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $13.21M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Mar 20, 2026 which is in 48 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on Nov 17, 2025. The company reported -$17.015 earnings per share for the quarter, missing the consensus estimate of -$6.583 by -$10.432.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -6.11.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 3,079,229 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$17.015 in its last earnings report, missing expectations of -$6.583. Following the earnings report the stock price went down -2.213%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in MBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moleculin Biotech
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
MBRX Stock 12 Month Forecast
Average Price Target
$24.33
▲(468.46% Upside)
Technical Analysis
Ownership Overview
35.72% Insiders
5.73% Mutual Funds
<0.01% Other Institutional Investors
50.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---